Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKB589 injection plus CAPOX and PD-1 inhibitor as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma
CTR20230016Phase 2Completed
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ASKB589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Aosaikang Biotherapeutics. Started Apr 2023; status: completed.
02
Drugs
ASKB589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20230016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230016.